Compare ACET & GPMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACET | GPMT |
|---|---|---|
| Founded | 1947 | 2015 |
| Country | United States | United States |
| Employees | N/A | 28 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.3M | 71.9M |
| IPO Year | 2017 | N/A |
| Metric | ACET | GPMT |
|---|---|---|
| Price | $7.38 | $1.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $48.33 | $3.00 |
| AVG Volume (30 Days) | 99.0K | ★ 154.0K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 12.99% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $458.85 |
| Revenue Next Year | N/A | $8.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $1.24 |
| 52 Week High | $9.47 | $3.12 |
| Indicator | ACET | GPMT |
|---|---|---|
| Relative Strength Index (RSI) | 42.41 | 49.49 |
| Support Level | $6.28 | $1.24 |
| Resistance Level | $8.68 | $1.58 |
| Average True Range (ATR) | 0.54 | 0.07 |
| MACD | -0.15 | 0.01 |
| Stochastic Oscillator | 11.01 | 46.94 |
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
Granite Point Mortgage Trust Inc focuses on directly originating, investing in, and managing senior floating rate commercial mortgage loans and other debt and debt-like commercial real estate investments. The company constructs its investment portfolio on a loan-by-loan basis, emphasizing rigorous credit underwriting, selectivity, and diversification, and assesses each investment from a fundamental value perspective relative to other opportunities available in the market. It typically provides intermediate-term bridge or transitional financing for a variety of purposes, including acquisitions, recapitalizations, refinancing, and a range of business plans, including lease-up, renovation, repositioning and repurposing of the commercial property.